SEARCH

SEARCH BY CITATION

References

  • Cassol S, Gill MJ, Pilon R, Cormier M, Voight RF, Willoughby B et al. (1997) Quantification of human immunodeficiency virus type 1 RNA from dried plasma spots collected on filter paper. Journal of Clinical Microbiology 35, 27952801.
  • Cipla Website (2004) Product information available at: http://www.cipla.com/ourproducts/Antiretrovirals/triomune1.htm. Accessed 13 September 2004.
  • Crowe S, Turnbull S, Oelrichs R & Dunne A (2003) Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clinical Infectious Diseases 37(Suppl. 1), 2535.
  • de Baar MP, van Dooren MW, de Rooij E, Bakker M, van Gemen B, Goudsmit J et al. (2001) Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. Journal of Clinical Microbiology 39, 13781384.
  • de Baar MP, Timmermans EC, Buitelaar M et al. (2003) Evaluation of the HIV-1 RNA RetinaTM rainbow assay on plasma and dried plasma spots: correlation with the Roche Amplicor HIV-1 v1.5 assay [abstract no. 1231]. Presented at: 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France.
  • Department of Health and Human Services (2004) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: http://AIDSinfo.nih.gov. Accessed 13 September 2004.
  • Donnerer J, Kronawetter M, Kapper A, Haas I & Kessler HH (2003) Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. Pharmacology 69, 197204.
  • Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC et al. (2000) Community-based approaches to HIV treatment in resource-poor settings. Lancet 358, 404409.
  • Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O & Salaniponi FM (2001) Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 358, 410414.
  • Kumarasamy N, Solomon S, Chaguturu SK et al. (2003) The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 17, 22672269.
  • HIVpharmacology Website (2004) http://www.HIVpharmacology.com. Accessed 13 September 2004.
  • Hollanders RM, Van Ewijk-Beneken Kolmer EW, Burger DM, Wuis EW, Koopmans PP, Hekster YA (2000) Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography B 744, 6571.
  • Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW et al. (2004) Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 18, 981989.
  • Malawi Ministry of Health and Population Website (2004) Available at: http://www.malawi.gov.mw/health/health2edoc.htm. Accessed 13 September 2004.
  • National Tuberculosis Control Programme, Ministry of Health HIV/AIDS Unit, Department of Clinical Services Ministry of Health, National AIDS Commission (2004) Report of a countrywide survey of HIV/AIDS services in Malawi (for the year 2003), Lilongwe, Malawi.
  • Oliva J, Moreno S, Sanz J, Ribera E, Molina JA, Rubio R et al. (2003) Co-administration of rifampicine and nevirapine in HIV infected patients with tuberculosis. AIDS 17, 637638.
  • Regazzi M, Villani P, Seminari E, Ravasi G, Cusato M, Marubbi F et al. (2003) Sex differences in nevirapine disposition in HIV-infected patients. AIDS 17, 23992400.
  • Ribaudo H, Clifford D, Gulick R, Shikuma C, Klingman K, Snyder S et al. (2004) Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: results from ACTG A5095/A5097s [Abstract 132]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
  • Tassie JM, Szumilin E, Calmy A & Goemaere E (2003) Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres. AIDS 17, 19951997.
  • Turner BJ (2002) Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. Journal of Infectious Diseases 185(Suppl. 2), S143S151.
  • Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA et al. (2001) High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 15, 10891095.
  • Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R et al. (2002) Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients’ response, survival, and drug resistance. Lancet 360, 3440.
  • WHO (2004) Staging System for HIV Infection and Disease in Adults and Adolescents. Available at http://www.who.int/docstore/hiv/scaling/anex1.html. Accessed 13 September 2004.
  • WHO Website (2004). Available at: http://www.who.int/3by5/about/en/. Accessed 13 September 2004.
  • World Health Organisation (2004) Scaling up Antiretroviral Therapy in Resource Poor Settings: Guidelines for a Public Health Approach 2003 Revision. Available at: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf. Accessed 13 September 2004.
  • Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA et al. (1999) Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrobial Agents and Chemotherapy 43, 121128.